DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.

Details

Serval ID
serval:BIB_CDC360A44460
Type
Article: article from journal or magazin.
Collection
Publications
Title
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.
Journal
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility To Chemicals
Author(s)
De Vriendt V., De Roock W., Di Narzo A.F., Tian S., Biesmans B., Jacobs B., Budinska E., Sagaert X., Rossi S., D'Ario G., Delorenzi M., Simon I., Vecchione L., Tejpar S.
ISSN
1366-5804 (Electronic)
ISSN-L
1354-750X
Publication state
Published
Issued date
2013
Volume
18
Number
6
Pages
516-524
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
As dual-specificity phosphatase (DUSP) expression has been correlated to sensitivity to MEK inhibitors, DUSP expression levels may indicate activation of the mitogen-activated protein kinase (MAPK) pathway in many tumor types. In this study, we investigate if DUSP levels can indicate different levels of MAPK activation within colorectal cancer (CRC) patients. In three different CRC patient microarray datasets, we analyzed the expression of DUSP1. DUSP4 and DUSP6 according to mutational status, their correlation with survival and their association with different clinical characteristics. DUSP4 was significantly differentially expressed between all mutational subgroups with the highest expression in BRAF mutated tumors. Moreover, high DUSP4 expression was associated with a worse overall survival and with clinical characteristics typical for BRAF mutant patients. The use of DUSP expression as a predictive biomarker towards MAPK targeted therapy in CRC patients needs further investigation.
Pubmed
Create date
28/02/2014 13:17
Last modification date
21/08/2019 5:35
Usage data